aPALACE 1-3 study. Data as observed; includes all patients with baseline psoriasis BSA >3 who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Patients with BSA ≥3 at baseline: OTEZLA 30 mg BID, n = 92/167 (55.1%); placebo, n = 94/169 (55.6%).
OTEZLA is also indicated for moderate to severe plaque psoriasis3
Week 16 PASI-75 result
Individual results may vary.
*Actual real-world OTEZLA patient. Property of Amgen Inc.
BID, twice daily; BSA, body surface area; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; PASI, Psoriasis Area and Severity Index.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).